Comparative effectiveness of home blood pressure telemonitoring (HBPTM) plus nurse case management versus HBPTM alone among Black and Hispanic stroke survivors: study protocol for a randomized controlled trial

Tanya M Spruill¹*, Olajide Williams², Jeanne A Teresi³, Susan Lehrer⁵, Liliana Pezzin⁶, Salina P Waddy⁷, Ronald M Lazar², Stephen K Williams¹, Girardin Jean-Louis³, Joseph Ravenell¹, Sunil Penesetti¹, Albert Favate⁸, Judith Flores⁹, Katherine A Henry⁸,¹⁰, Anne Kleiman¹¹, Steven R Levine¹²,¹³,¹⁴, Richard Sinert¹⁵, Teresa Y Smith¹⁵, Michelle Stern¹⁶, Helen Valsamis¹²,¹⁷ and Gbenga Ogedegbe¹

Abstract

Background: Black and Hispanic stroke survivors experience higher rates of recurrent stroke than whites. This disparity is partly explained by disproportionately higher rates of uncontrolled hypertension in these populations. Home blood pressure telemonitoring (HBPTM) and nurse case management (NCM) have proven efficacy in addressing the multilevel barriers to blood pressure (BP) control and reducing BP. However, the effectiveness of these interventions has not been evaluated in stroke patients. This study is designed to evaluate the comparative effectiveness, cost-effectiveness and sustainability of these two telehealth interventions in reducing BP and recurrent stroke among high-risk Black and Hispanic stroke survivors with uncontrolled hypertension.

Methods/Design: A total of 450 Black and Hispanic patients with recent nondisabling stroke and uncontrolled hypertension are randomly assigned to one of two 12-month interventions: 1) HBPTM with wireless feedback to primary care providers or 2) HBPTM plus individualized, culturally-tailored, telephone-based NCM. Patients are recruited from stroke centers and primary care practices within the Health and Hospital Corporations (HHC) Network in New York City. Study visits occur at baseline, 6, 12 and 24 months. The primary outcomes are within-patient change in systolic BP at 12 months, and the rate of stroke recurrence at 24 months. The secondary outcome is the comparative cost-effectiveness of the interventions at 12 and 24 months; and exploratory outcomes include changes in stroke risk factors, health behaviors and treatment intensification. Recruitment for the stroke telemonitoring hypertension trial is currently ongoing.

(Continued on next page)
Discussion: The combination of two established and effective interventions along with the utilization of health information technology supports the sustainability of the HBPTM + NCM intervention and feasibility of its widespread implementation. Results of this trial will provide strong empirical evidence to inform clinical guidelines for management of stroke in minority stroke survivors with uncontrolled hypertension. If effective among Black and Hispanic stroke survivors, these interventions have the potential to substantially mitigate racial and ethnic disparities in stroke recurrence.

Trial registration: ClinicalTrials.gov NCT02011685. Registered 10 December 2013.

Keywords: stroke, hypertension, blood pressure, disparities, telehealth, comparative effectiveness research

Background

Despite progress in the reduction of stroke mortality for the general U.S. population [1], Blacks and Hispanics continue to experience worse stroke-related outcomes compared with whites, including higher rates of recurrent stroke [2-8]. While the reasons for this disparity are complex, epidemiologic studies show that Black and Hispanic stroke survivors have worse secondary stroke risk factor profiles compared with whites, including higher rates of uncontrolled hypertension, diabetes, and hyperlipidemia [9-14]. Of these risk factors, hypertension is the most important intervention target [15]; a systematic review found that a 10-mm Hg reduction in systolic blood pressure (SBP) was associated with a 31% reduction in risk of recurrent stroke [16]. There is evidence that the impact of elevated SBP on stroke risk is three times greater for Blacks than for whites [17]. Thus, interventions targeting BP reduction in minorities have the potential to substantially mitigate racial and ethnic disparities in stroke recurrence.

Both medical and behavioral interventions have been proven effective in improving BP control in hypertensive patients [18]; however, translation of this evidence to improved health outcomes is suboptimal. Among stroke patients, poor BP control results from barriers that exist at multiple levels of care including the patient, the physician, and the healthcare system [19-21]. Up to one-third of stroke patients report poor adherence to antihypertensive medications, which is associated with increased risk of death after stroke [22] and is more common in minority patients compared with white patients [23,24]. Poor adherence to hypertension treatment guidelines is another significant barrier, particularly in the care of Black patients [25,26]. Even when providers adhere to guidelines, physicians often lack appropriate aggressiveness in the use of antihypertensive medications [27-29]. With respect to the healthcare system, Black and Hispanic patients with stroke report poorer access to care and medications compared with their white counterparts [30,31]. Further, poor integration of clinical decision support tools into daily practice and lack of integration of self-management interventions with robust health information technology platforms may contribute to suboptimal BP control in minority populations [32,33]. Improving BP control and reducing recurrent stroke among minority stroke survivors will require complex strategies that address barriers at each of these levels.

Two such interventions are (1) home BP telemonitoring (HBPTM) that provides regular feedback on BP levels to patients and their providers, which engages patients in their care, improves medication adherence, and reduces clinical uncertainty and inertia [34-36]; and (2) telephonic nurse case management (NCM), which provides education and individual support to enhance patient adherence to prescribed medications, self-management behaviors, and patient-provider collaboration [37-40]. Clinical trial evidence of the effectiveness of HBPTM and NCM for BP reduction is well documented. However, their widespread implementation in primary care practices has been hindered by the lack of scalability and sustainability, their labor-intensive nature, the lack of integration into the primary care infrastructure, and the absence of data on their comparative and cost-effectiveness. Further, the utility of these interventions among Black and Hispanic stroke patients remains unproven. The proposed practice-based stroke telemonitoring hypertension trial is designed to address these critical gaps in the literature.

Study aims

The aim of this study is to evaluate the comparative effectiveness, cost-effectiveness and sustainability of home BP telemonitoring (HBPTM) alone versus HBPTM plus tailored, telephone-based NCM to reduce BP and prevent recurrent stroke among Black and Hispanic stroke survivors with uncontrolled hypertension. The combined HBPTM + NCM intervention we are evaluating is the ‘House Calls’ program offered through the New York City Heath and Hospitals Corporation (HHC). This established telehealth program utilizes an interactive web-based system to integrate HBPTM with personalized care, education and disease management from experienced nurses and has been shown to achieve significant reductions in BP [41]. There is evidence suggesting that the combination of home BP monitoring and NCM may be more
effective in reducing BP than either intervention alone, particularly with respect to sustainability of effects [42,43].

Methods/Design
Overview of study design
This is a practice-based, multisite comparative and cost-effectiveness randomized controlled trial. Each patient will be randomly assigned to one of two 12-month interventions: 1) home BP telemonitoring (HBPTM) or 2) HBPTM plus tailored telephone-based nurse case management (HBPTM + NCM). We will recruit 450 Black and Hispanic patients with nonsevere poststroke disability and uncontrolled hypertension from the HHC Network - a municipal healthcare system that serves more than 1.8 million urban and diverse patients.

The primary hypothesis is that supplementing HBPTM with tailored NCM will lead to greater reduction in SBP and stroke recurrence rate than HBPTM alone at 12 and 24 months, respectively. The secondary hypothesis is that the combined HBPTM + NCM intervention will be more cost-effective than HBPTM alone in reducing SBP and recurrent stroke. In exploratory analyses, we will assess changes in physicians’ treatment decisions, patients’ health behaviors, and other stroke risk factors, and will evaluate their role as mediators of intervention effects. The study design is shown in Figure 1.

Research setting
The New York City Health and Hospitals Corporation (HHC) is an integrated municipal healthcare delivery system that serves more than 1.4 million New Yorkers every year, of whom more than 475,000 are uninsured. It is the largest municipal healthcare organization in the United States. Many HHC facilities are designated AHA Stroke Centers of Excellence, where stroke patients receive quality care and urgent diagnosis and treatment. The stroke telemonitoring hypertension trial is being implemented at the following HHC hospitals: Jacobi Medical Center, Bellevue Hospital Center, Harlem Hospital Center, Kings County Hospital Center and Woodhull Medical Center. The study protocol has been approved by the Institutional Review Boards of New York University School of Medicine (i13-00281), the Biomedical Research Alliance of New York (BRANY; 13-02-227 (HHC)-11), the Medical College of Wisconsin (PRO00019839) and the Hebrew Home for the Aged at Riverdale (03121/P084/02).

Patient population
Eligibility criteria were chosen to be as inclusive as possible while accounting for patients’ ability to participate in the interventions and to complete the 2-year study. The following inclusion and exclusion criteria are evaluated during a multistep screening process using a combination of EHR review, patient self-report and external stroke adjudication.

Inclusion criteria
Inclusion criteria are as follows:

- Age 18 years or older

Figure 1 Study design.
- Black or Hispanic
- Fluent in English or Spanish
- At least one month post-discharge for ischemic or hemorrhagic stroke
- Modified Rankin Scale [44] score of ≤3, indicating nonsevere poststroke disability
- Screening SBP ≥140 mm Hg, defined by the average of three BP readings taken at each of two visits
- Patient plans to continue receiving care at the study site for the next two years

**Exclusion criteria**
Exclusion criteria are any of the following:

- Moderate to severe cognitive impairment as indicated by a score of ≥6 on the Comprehensive Assessment and Referral Evaluation (CARE)-Diagnostic Scale [45-47]
- Significant psychiatric comorbidity (indicated in EHR or self-reported)
- Significant verbal speech impairment (unable to complete screening)
- Unable to comply with the HBPTM and/or NCM protocols (either self-selected or apparent during screening that patient could not complete all required tasks)
- Upper arm circumference ≥52 cm, the maximum limit of the extra-large BP cuff
- Dialysis or diagnosis of end stage renal disease (indicated in EHR or self-reported)
- Relocating out of area or extended travel during study period
- Participation in other interventional clinical trials
- Pregnancy

**Study procedures**

**Recruitment**
Patients are recruited using two main approaches: (1) identification of potentially eligible patients from Stroke Center admission and discharge lists and (2) ongoing review of the electronic health records (EHRs) at HHC primary care or outpatient neurology/stroke practices using ICD-9 codes for hypertension and stroke. At the beginning of the study at each study site, the project coordinator works with clinic leadership to develop a process for recruitment at that site. Clinic staff members are given a laminated pocket card with the eligibility criteria and research assistant (RA) contact information to facilitate referrals. Physicians of potentially eligible patients are asked to describe the study to their patients briefly and obtain permission for research staff to contact the patients. Those who are interested and potentially eligible are scheduled for screening.

**Screening and baseline visits**
All interactions between the RA and the patient are in English or Spanish, depending on the patient’s preference. After obtaining written informed consent, the RA takes three BP measurements using the Microlife Watch BP Office, a validated automated BP device (see www.dableducation.org), following American Heart Association guidelines [48]. Patients with an average SBP ≥140 mm Hg are scheduled for a second eligibility visit within 3 to 14 days, at which time a second BP measurement is taken. Patients must have an average SBP ≥140 mm Hg at each of the two screening visits to be eligible. To assess other eligibility criteria, the RA administers a computer-assisted personal interview (CAPI) programmed by the Research Core (see Data Management section below), which includes the CARE-Diagnostic Scale, modified Rankin Scale and other self-report items. Patients who are eligible are scheduled for a baseline visit, at which time the RA takes measurements of height, weight, waist circumference and BP and administers the baseline interview; self-report measures included in this interview are listed in the Study Measures section below.

**Randomization**
Once baseline assessments are completed, all relevant records related to the patient’s stroke admission are abstracted from the EHR and sent to the adjudication committee for review. Once the adjudicators have confirmed the diagnosis of stroke, the Research Core performs the randomization procedure. The RA informs the patient of the assigned study arm and enters him/her into the telehealth web portal, which triggers delivery of the HBPTM device to the patient’s home and contact from a NCM. Randomization is within primary care physician on a 1:1 assignment to the two treatment arms.

**Follow-up visits**
The RA meets with the patient at 6, 12 and 24 months to collect self-report data and BP measurements using the automated BP device. Patients’ EHRs are also reviewed at each time point. Visits are scheduled to coincide with regularly scheduled appointments at the patient’s hospital, but may be conducted in the patient’s home if needed.

**Compensation**
Patients receive $10 compensation for each of the two eligibility visits, $30 for the baseline visit, $40 for the 6-month visit, $50 for the 12-month visit and $50 for the 24-month visit, for a possible total compensation of $190.

**Data and safety monitoring plan**
Adverse events are reported to the appropriate institutional review boards (IRBs) and Privacy Boards. To ensure
the safety of participants and the validity and integrity of the data, a data and safety monitoring board (DSMB) was established and meets approximately every six months. The DSMB includes senior investigators with expertise in stroke, hypertension, and biostatistics.

Study interventions

Home blood pressure telemonitoring

Participants in both groups receive an automated home BP monitoring device (A&D UA-767 Plus) that has been validated for the measurement of BP by the British Hypertension Society and is recommended at www.bshs.org.uk. This device has the telemonitoring capability to transfer patients’ BP measurements wirelessly to a secure server in real time, without any action by the patient. The BP readings can then be disseminated to intended targets: the research team, the NCMs, and patients’ physicians. The patient also sees the BP readings when she or he takes the measurements, and is asked to keep a paper-and-pencil log of the readings, which has been shown to enhance self-management and adherence. For safety measures, the monitors are pre-programmed with BP alarm values (below 90 and/or 55 mmHg or above 180 and/or 110 mmHg), which when triggered, activate an e-mail or SMS message to the research staff or NCM, depending on study group assignment, prompting follow-up with the patient. All patients are trained by an RA in the use of the HBPTM device and instructed to take their BP twice in the morning and twice in the evening, three days a week during the 12-month intervention.

Patients randomized to the HBPTM alone group receive printed educational materials on management of hypertension and stroke developed by NHLBI in English or Spanish as preferred. The NCM contacts patients within 2 weeks to make sure they are comfortable using the HBPTM device and to review the educational materials. The patient’s physician receives home BP reports via secure email before every scheduled appointment for the duration of the study. At the end of the study, the patient will be asked to return the home BP monitor to study staff. All BP readings stored in the actual monitor will be deleted.

Home blood pressure telemonitoring plus nurse case management

The combined intervention, the HouseCalls telehealth program, is integrated into the HHC system as part of its home care program. The intervention is delivered by HHC nurses who have real-time access to patients’ EHRs and are in communication with their providers. After randomization and delivery of the HBPTM device to patients’ homes, the NCM contacts patients within two weeks to make sure they are comfortable using the device. The NCM then initiates the planned schedule of counseling phone calls: weekly calls for months 1 to 2, biweekly calls for months 3 to 4, and then monthly calls for months 5 to 12; more frequent calls may be completed at the NCMs discretion. Each call lasts between 15 and 45 minutes depending on the needs of the patient. The NCM has access to patients’ home BP data via a secure website, where the BP readings are displayed in easy-to-read charts and figures that highlight the control rate for each week. This information is used by the NCM as a basis for the counseling sessions. Patients’ physicians have access to this website, and also receive home BP reports via secure email before every scheduled appointment for the duration of the study.

During the scheduled telephone sessions, the NCM provides self-management education and medication and appointment reminders, and facilitates patient-provider communication. The NCM works with the patient to set behavioral goals based on individual needs. Target behaviors discussed may include dietary changes, physical activity, weight loss, medication adherence, and smoking cessation. The NCM assesses the patient’s barriers to behavior change and use problem-solving and motivational interviewing techniques to support behavior change efforts. At the end of each counseling session, the NCM records the notes of the encounter in the web portal and communicates with the patient’s physician if needed (for example, regarding medication side effects or other problems reported by patients, or the need for appointments or medication refills). The NCM also reviews the patient’s clinical information and provides feedback of abnormal lab results. Thus, the intervention addresses patient-level issues (adherence, self-management), provider-level issues (clinical inertia), and system issues (web-based HBPTM integration into EHR, embedded NCM).

Treatment fidelity

Our efforts to maximize the quality and consistency of the interventions include (1) careful training of patients in the use of the home BP monitors; (2) strategies to enhance patient adherence to each of the interventions (that is, reminder calls, monitoring transmission of home BP readings, weekend availability for NCM sessions); and (3) monitoring of adherence to the interventions to evaluate consistency across study sites and, for the HBPTM + NCM arm, across nurses. A key strength of this study is the use of an established, successful NCM intervention that does not require extensive training or supervision from research staff, aside from details of the study protocol. The nurses working with the House Calls program have undergone extensive training in principles and strategies of behavior change needed for effective counseling of chronic disease patients (for example, motivational interviewing skills, problem-solving approaches). To provide data on intervention content for secondary analyses,
the nurses complete a checklist following each counseling session to indicate the topics covered.

Data collection and management
This study has a Research Core that is responsible for the following activities: 1) development of the computer-assisted data collection system, 2) staff training and certification in data collection, 3) randomization procedures, 4) data monitoring and quality control, 5) data processing, and 6) data analysis. The Research Core prepares regular reports for internal and external monitoring of progress toward study milestones, and will provide blinded and unblended data requests for DSMB meetings.

Study measures
The primary outcomes are within-patient change in SBP from baseline to 12 months and stroke recurrence rates at 24 months. Secondary outcomes are 12- and 24-month cost-effectiveness. Exploratory outcomes include 1) physicians’ hypertension medication intensification [49]; (2) patients’ health behaviors (diet, physical activity, medication adherence); and (3) other important stroke risk factors (blood glucose, lipids).

Blood pressure
BP is measured at each study visit by a trained RA using a validated automated BP monitor (Microlife WatchBP Office), following the American Heart Association (AHA) guidelines [48]. The device is programmed to take three readings at 2-minute intervals after an initial rest period of 3 minutes. The patient is asked to sit quietly without talking during the measurement period. The three automated readings are averaged to give the final SBP measurement for each visit.

Stroke recurrence
All participants are urged to contact research staff as soon as any event that might be a stroke has occurred. If research staff members learn from a participant, family member, NCM or physician that a stroke might have taken place, all clinical, laboratory and imaging data needed to confirm the event are extracted from the EHR by the RA and sent to the Research Core within one week. These materials are then provided to the two blinded adjudicators for independent review using the National Institute of Neurological Disorders and Stroke (NINDS) Stroke Adjudication Worksheet [50,51]. Final reports regarding the event will be returned to the Research Core within 15 days. If the two adjudicators have different opinions, the materials will be sent to a third adjudicator. The Research Core records the final decision.

Self-report measures
Patient interviews at baseline, 6 months, 12 months and 24-months are the source of data for analyses of other study outcomes. The selection of study measures was guided by the NINDS Stroke Common Data Elements (CDEs) [51] in order to promote standardization with the larger body of stroke research. Some of the measures we require to test our hypotheses are not included in the Stroke CDEs; for these we selected widely used, validated measures. All study materials not already available in Spanish were translated by a professional translation service. The interview instrument includes measures of 1) demographics and socioeconomic status; 2) behavioral history (alcohol, nicotine, drug use); 3) family medical history; 4) Charlson Comorbidity Index [52]; 5) executive function (Frontal Assessment Battery) [53]; 6) depression (PROMIS Depression short-form) [54]; 7) disability (Modified Rankin Scale [44]); 8) functional status (the Barthel Index [55]); 9) health-related quality of life (EuroQoL [56]); 10) medication adherence (Morisky Medication Adherence Scale [57]); 11) diet (NCI Percentage Energy from Fat Screener) [58]; 12) physical activity (International Physical Activity Questionnaire) [59]; and 13) a healthcare utilization questionnaire that collects information on hospitalizations, emergency department (ED) visits, health insurance and medications developed by the investigators.

Anthropometric measurements
A stadiometer is used to measure height, a validated digital scale for weight, and a tape measure specifically designed for accurate and repeatable measurements of various body dimensions for waist circumference. All height and waist circumference measurements are recorded to the nearest 0.1 cm and all weight measurements are recorded to the nearest 0.1 kg respectively. All measurements are taken without shoes and with light clothes.

Electronic health record data
Patients’ electronic health records (EHRs) are reviewed following each study visit to extract information regarding hypertension characteristics and treatment (that is, medications, dosages, and physician notes), comorbidity, and relevant lab results (that is, blood glucose, lipids). EHRs are also the source of information for certain cost data, including direct costs to third party payers.

Cost data
In addition to expenses associated with implementation of the two interventions, cost measures include resource costs associated with direct health care costs, including use of ambulatory care services, such as physician and ED visits, laboratory tests, hospitalizations, surgical procedures, and medication regimens. Intervention costs will include all
direct (labor) and indirect (overhead) incremental costs associated with implementation of the interventions - most notably, labor and equipment costs associated with HBPTM, costs of producing and distributing educational materials, and costs associated with the NCM’s time. Unit costs of interventions will be measured by detailed resource-cost analyses of the time of involved health professionals and supplies or equipment. Utilization of health care services is obtained from EHRs and patient surveys. The unit costs of ambulatory services are obtained from clinic billing records and the costs of medications from prescribed regimens and the Red Book prices for the prevailing years.

Sample size and power analysis
The primary hypotheses are (a) a greater reduction in systolic BP over three waves of data: baseline, 6 and 12 months and (b) a lower 24-month stroke recurrence rate among the combined HBPTM + NCM group compared to the HBPTM alone group. Although there may be more than one episode of stroke per patient, given the sample size, we will combine all events. We assume separate analyses of the outcomes, with pre-specified \( \alpha = 0.05 \) for each outcome. Statistical modeling procedures will be used that allow the inclusion in the analysis of participants who do not complete the follow-up assessment (on an intent-to-treat basis). The approach to the power calculations incorporates the design feature of clustering. The cluster size of participants who are eligible (uncontrolled hypertension with a history of stroke) within PCP is estimated to range from 5 to 6. Data from a similar study of telemedicine (IDEATel) delivered to New York City Hispanics and Blacks did not show heterogeneous variances [60], so this scenario was not included in power calculations. Specific types of selection bias and attrition were considered.

Based on studies of telemedicine in Blacks and Hispanics [42,43,60-62], it was estimated that the baseline and longitudinal standard deviations of SBP at baseline will be between 18 and 22 mm Hg. The observed mean differences were from 3 to 8 for SBP. We posited that the enhanced telemedicine intervention will result in an effect size ranging from a 6- to 8-point difference in SBP. The assumptions were as follows: \( \alpha = .05 \) for a two-tailed test; \( 1 - \beta = .80 \) and above; and \( \delta = \mu_1 - \mu_2 = 6, 7, 8 \) (SBP point reduction). The following assumptions were used in the power calculations: \( R = 0.90 \) (reliability); \( g = 2 \) (groups), pooled \( \sigma = 20.75 \) (baseline control: 19.6; intervention 19.2; 6 month control: 21.7; intervention: 20.5; 12 month control: 21.0; intervention: 22.3), \( d = \delta / \sigma \) (where \( \delta \) is difference in end study and \( d \) is Cohen’s \( d \)) [63]. The cluster size was estimated as 5; the intracluster correlation (ICC) = 0.03; and \( Vif = 1 + (\text{clustersize} - 1)^*\text{ICC} = 1.12 \).

Power for comparing rates of change in systolic blood pressure response over 12 months between groups
The power to detect a difference in slopes \( (\beta_{1A} - \beta_{1B}) \) over the twelve months of the study (using all waves of data) was examined. An estimate of the required sample sizes [64,65], is given, considering time measured as the duration between the first and jth occasion, \( j = 0, 0.5, 1 \) year. The assumptions above were used regarding design effects and reliability; these calculations assume that \( p = 0.5, 0.6 \) (the average correlation between baseline and follow up) and \( \delta = 6, 7 \) (SBP = yearly point reduction). Based on examination of endpoint differences, the required sample sizes ranged from 175 to 225, depending on the assumptions regarding effect sizes [66]. The selected sample size of 225 per group permits detection of relatively small effect sizes, ranging from 5 to 6, depending on different scenarios.

Power for the stroke recurrence outcome at 24 months
Power was examined for stroke recurrence outcomes using the sample size formula for the log-rank test, where \( d \) is the expected probability of an event over subjects and is the hazard ratio. An additional calculation examining time-to-event using a Cox model was also performed. The assumptions were as above regarding reliability, cluster size and intracluster correlation coefficient. The correlation between pre- and post-measures was set at 0.60. A sample size of between 208 and 223 per group is needed, depending on the model and assumptions for 80% power to detect a 10% intervention group reduction in the rate of stroke at 24 months from a baseline rate of 15% [67].

Summary
Conservatively, under the assumptions specified above, 225 subjects per group will provide power ≥0.80 to detect the hypothesized 6 to 8 unit differential change in SBP, based on testing the Time X Group interaction in a mixed model, adjusting for unreliability, design effects due to clustering and serial correlations. This sample size will also provide power ≥0.80 to detect the hypothesized 10% group reduction in the rate of stroke at 24 months from a baseline rate of 15%.

Analytic plan
Primary hypotheses: patients randomized to HBPTM + NCM will have (a) greater reduction in SBP at 12 months, and (b) lower rates of stroke recurrence at 24 months, compared to those in HBPTM alone
The analyses of SBP change will use mixed random effects models, and a full information maximum likelihood approach, with sensitivity analyses using generalized estimating equations. The change from pre- to post-treatment values of continuous outcomes will be modeled as functions of treatment group, time and the interaction of time
and treatment. The intent-to-treat analyses performed using SAS PROC MIXED will permit modeling design effects (clustering), and allow for the possible group heterogeneity in residual variances and serial correlations that may require modeling to satisfy model assumptions and improve model fit. Based on prior analytic experience with the outcome variables, it is not expected that transformations will be necessary. Analyses of 24-month stroke recurrence will be performed using the log rank test or a Cox model examining time-to-event, should covariates be required.

Prior to analyses, baseline values of all variables from each arm will be examined; however, no P values will be provided, and covariates are not proposed for inclusion in the main analyses of treatment effects. If one or more sources of potential (selection or attrition) bias are identified, the predicted values from those analyses will be included as covariates in secondary analyses. Depending on the severity of missing data, other modeling techniques may be used.

Since the analysis and inference is based on intent-to-treat, an attempt will be made to obtain post-treatment data from all randomized participants, regardless of their adherence to the interventions. Nonetheless, secondary analyses will be conducted to investigate the impact of differential participation, stratifying participants in the treatment conditions based on their degree of participation and examining differences between strata on the outcome measures at follow-up.

**Secondary hypotheses: HBPTM + NCM will be more costly but also more cost-effective in reducing (a) SBP at 12 months and (b) stroke recurrence at 24 months than HBPTM alone**

The principal measures of cost to be used in the study pertain to (i) intervention-related resource costs and (ii) overall direct health care costs. To assess cost differences in intervention and overall costs across interventions, we will first compare average patient costs across the two groups. Patient-level analyses of costs, similar to those described above for outcomes, will be used to produce regression-adjusted measures of cost-effectiveness for each intervention. Using methods consistent with the standards published in 1996 [68-70], we will conduct incremental cost-effectiveness analyses (CEAs) to assess the relative effects of the interventions on three time periods: intervention period (12 months), follow-up period (24-months post-randomization), and lifetime perspective. Measures of effectiveness in the intervention and follow-up period CEAs will be based on differences across intervention groups in (1) mean changes in SBP (mm Hg); (2) stroke recurrence; and (3) quality of life (as measured by EuroQol scores). Bootstrapping procedures will be applied to obtain confidence intervals around all of our cost-effectiveness estimates. Sensitivity analyses will be used to examine key uncertainties about CEA findings by identifying variables that have the most dramatic effects on estimated CE ratios and examining the effects of changes in these measures/assumptions on CEA results.

**Exploratory analysis of potential mediators and moderators**

We will conduct exploratory analyses to test potential mediating pathways involving (1) changes in other stroke risk factors (that is, lipids, blood glucose); (2) changes in health behaviors (that is, diet, physical activity, medication adherence); and (3) antihypertensive medication intensification (that is, adding or changing dose or class of medications). We will first compare effects of the two interventions on each of these outcomes, following the analysis plans detailed above for continuous and dichotomous variables as appropriate. We will then use formal tests to examine the extent to which the intervention effects are mediated through these variables. Since we have no reason to assume that effects of the interventions will differ by race/ethnicity or by site, our primary analyses do not stratify by these factors or include interaction effects. That said, we will conduct exploratory analyses to examine whether or not the interventions are equally effective for Black and Hispanic patients, and across study sites [71-73].

**Discussion**

Disparities in stroke remain a major public health problem in the United States. There is an urgent need for secondary prevention strategies that can help to reduce disproportionally higher rates of recurrent stroke among Black and Hispanic patients. Many interventions to improve BP control have been developed and tested, and several have been proven effective under controlled conditions [74-77]. However, if these interventions cannot find a place in primary care practices, their impact on public health will be negligible. Progress toward this goal has been hindered by lack of comparative effectiveness and cost-effectiveness data, particularly in minority populations, and insufficient utilization of health information technology that is needed to support their dissemination and long-term sustainability in community-based primary care practices where the majority of low-income minority patients receive their care. Two potentially viable interventions in this respect are home BP monitoring and telephone-based NCM, both of which have proven efficacy in improving BP control and may reduce the risk of recurrent stroke. Adoption of these interventions at the primary care level may also reduce the risk of incident stroke, which contributes even more heavily than recurrent stroke to disparities [78].

A major limitation of previous studies of NCM and home BP monitoring is their lack of sustainability and scalability. This is largely due to the intensive nature of
the delivery of these interventions, which often requires multiple office visits and patient counseling sessions. The ongoing stroke telemonitoring hypertension trial addresses this limitation by using well-established web-based and wireless technologies, which are easily deployable, efficient and potentially cost-effective. The merging of two established and effective interventions along with the utilization of health information technology supports the sustainability of the HBPTM + NCM intervention and feasibility of its widespread implementation. Embedding care managers within practices further facilitates sustainability particularly in the current climate of outcome-based payment reform. Cost-effectiveness analysis is an integral objective of this study given the enormous financial burden of stroke. The American Heart Association projects that direct costs of stroke will increase 238% from 2010 to 2030 and indirect costs will increase 73%; total costs are projected to increase from $53.9 billion in 2010 to $140 billion in 2030 [79]. Thus cost-effective secondary stroke prevention interventions have the potential to produce enormous savings, particularly in the care of minority patients who suffer disproportionately higher stroke-related morbidity and mortality.

If successful, these telehealth interventions can be relatively easily adapted and incorporated into the care of 1.4 million New Yorkers who receive care within the HHC network. MetroPlus, HHC’s 420,000-member health plan, already reimburses for the House Calls program among patients with poorly controlled diabetes and congestive heart failure. Demonstrating the comparative- and cost-effectiveness of this program among stroke patients with uncontrolled hypertension may facilitate the process of expanding coverage for this intervention for this high-risk population as well. Ultimately, we envision implementation beyond our study population across the larger HHC population as well. Ultimately, we envision implementation beyond our study population across the larger HHC community and other local healthcare systems, as well as other urban communities that, like NYC, have large populations of underserved minorities who would benefit from secondary stroke prevention interventions.

**Trial status**

Recruitment for this study began in December 2013 and is ongoing.

**Abbreviations**

BP: blood pressure; CEA: cost-effectiveness analysis; EHR: electronic health record; HBPTM: home blood pressure telemonitoring; HHC: Health and Hospital Corporations; IRB: institutional review board; NCM: nurse case management; RA: research assistant; RCT: randomized controlled trial; SBP: systolic blood pressure.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

GO is the overall Principal Investigator of the study and obtained funding. GO, TMS, OW, JAT, SPW, RML, SL, RS, GJL and JR contributed to the study design. JAT and LP were responsible for the analysis plan. TMS is overseeing implementation of the protocol and drafted the manuscript. JAT, SL, SKW, SP, AF, JF, KAH, AK, SRL, RS, TYS, MS and HV are contributing to implementation of the protocol and acquisition of data. All authors read and approved the final manuscript.

**Acknowledgements**

This study is supported by the National Institute of Neurological Disorders and Stroke (U54 NS081765). The authors thank Leanne Leurassi, MPH, Stephanie Silver, MPH, Sueann Godfrey, MPH, and Amy Zarrow, RN for their support and assistance with this trial.

**Author details**

1. New York University School of Medicine, 227 East 30th Street, Room 640, 10016 New York, NY, USA. Departments of Neurology, Columbia University Medical School, New York, NY, USA. 2. Research Division, Hebrew Home at Riverdale, Bronx, NY, USA. 3. Columbia University Stroud Center and New York State Psychiatric Institute, New York, NY, USA. 4. Health and Hospitals Corporation, New York, NY, USA. 5. Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. 6. Office of Clinical Research, National Institutes of Health, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA. 7. Department of Neurology, New York University School of Medicine, New York, NY, USA. 8. Woodhull Medical Center, New York, NY, USA. 9. Bellevue Hospital Center, New York, NY, USA. 10. Harlem Hospital, New York, NY, USA. 11. Department of Neurology, SUNY Downstate Medical Center, Brooklyn, NY, USA. 12. Department of Emergency Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA. 13. The Department of Neurology, Kings County Hospital Center, Brooklyn, NY, USA. 14. Department of Emergency Medicine, Kings County Health Center, Brooklyn, NY, USA. 15. Jacobi Medical Center, New York, NY, USA. 16. Neurology Service, Kings County Hospital, Brooklyn, NY, USA.

**Received**: 13 August 2014 **Accepted**: 12 February 2015 **Published online**: 15 March 2015

**References**

1. Lackland DT, Roccella EJ, Deutsch AF, Fornage M, George MG, Howard G, et al. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke. 2014;45:315–53.
2. Morgenstern LB, Smith MA, Lisabeth LD, Risser JM, Uchino K, Garcia N, et al. Excess stroke in Mexican Americans compared with non-Hispanic Whites: the Brain Attack Surveillance in Corpus Christi Project. Am J Epidemiol. 2004;160:736–83.
3. Lisabeth LD, Smith MA, Brown DL, Moye LA, Risser JM, Morgenstern LB. Ethnic differences in stroke recurrence. Ann Neurol. 2006;60:469–75.
4. Ottenbacher KJ, Campbell J, Kuo YF, Deutsch A, Ostr GL, Granger OJ. Racial and ethnic differences in postacute rehabilitation outcomes after stroke in the United States. Stroke. 2008;39:1514–9.
5. Broderick J, Brott T, Kothari R, Miller R, Khoury J, Pancioli A, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke. 1998;29:415–21.
6. Feng W, Hendry RM, Adams RJ. Risk of recurrent stroke, myocardial infarction, or death in hospitalized stroke patients. Neurology. 2010;74:598–93.
7. Kennedy BS. Does race predict stroke readmission? An analysis using the truncated negative binomial model. J Natl Med Assoc. 2005;97:699–713.
8. Shennar KF, Tuhrim S, Horowitz DR, Weinberger J, Goldman M, Godbold JH. Stroke recurrence is more frequent in Blacks and Hispanics. Neuroepidemiology. 1998;17:188–98.
9. Cushman M, Cantrell RA, McClure LA, Howard G, Prineas RJ, Moy CS, et al. Estimated 10-year stroke risk by region and race in the United States: geographic and racial differences in stroke risk. Ann Neurol. 2008;64:507–13.
10. Boden-Alba B, Sacco RL, Lee HS, Gahane-Clarke C, Rundek T, Ekin MV, et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Stroke Study. Stroke. 2008;39:30–5.
11. Thomas AJ, Eberly LE, Davey Smith G, Neaton JD, Stamler J. Race/ethnicity, income, major risk factors, and cardiovascular disease mortality. Am J Public Health. 2005;95:1417–23.
12. Morgenstern LB, Steffen-Batey L, Smith MA, Moye LA. Barriers to acute stroke therapy and stroke prevention in Mexican Americans. Stroke. 2001;32:1390–4.
13. Bravata DM, Wells CK, Gulanik B, Kernan WN, Brass LM, Long J, et al. Racial disparities in stroke risk factors: the impact of socioeconomic status. Stroke. 2003;36:1507–11.

14. McGuire HF, Malarchar AM, Antoine TL, Greenlund KJ, Crotty JB. Racial and ethnic disparities in cardiovascular risk factors among stroke survivors: United States 1999–2001. Stroke. 2004;35:1557–61.

15. Sacco RL, Adams RJ, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:517–61.

16. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke. 2004;35:1024.

17. Howard G, Lackland DT, Kleindorfer DO, Kissela BM, Moy CS, Judd SE, et al. Racial differences in the impact of elevated systolic blood pressure on stroke risk. JAMA Intern Med. 2013;173:46–51.

18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–52.

19. Weber MA. Strategies for improving blood pressure control. Am J Hypertens. 1998;11:897–9.

20. Hill MN, Sutton BS. Barriers to hypertension care and control. Curr Hypertens Rep. 2002;4:465–50.

21. Alderman MH. Barriers to blood pressure control. Am J Hypertens. 1999;12(12 Pt 1):1268–9.

22. Khan NA, Yun L, Humphries K, Kapral M. Antihypertensive drug use and adherence after stroke: are there any differences? Stroke. 2010;41:1445–9.

23. Munro P, Halanych J, Reynolds K, Durant R, Vuppunturi S, Sung WY, et al. Low medication adherence and the incidence of stroke symptoms among individuals with hypertension: the REGARDS study. J Clin Hypertens. 2011;13:479–86.

24. Adams AS, Urrutia C, Dyer W, Magid D, O’Connor P, Beck A, et al. Health system factors and antihypertensive adherence in a racially and ethnically diverse cohort of new users. JAMA Intern Med. 2013;173:54–61.

25. Mehta SS, Wilcox CS, Schulman KA. Treatment of hypertension in patients with comorbidities: results from the study of hypertension prescribing practices (SHyPP). Am J Hypertens. 1999;12(12 Pt 1):1–24.

26. Khan NA, Yun L, Humphries K, Kapral M. Antihypertensive drug use and adherence after stroke: are there any differences? Stroke. 2010;41:1445–9.

27. Ballard DJ, Strogatz DS, Wagner EH, Siscovick DS, James SA, Kleinbaum DG, et al. Evaluating the influence of complications on the final goal. South Med J. 1958;51:605.

28. Adams AS, Urrutia C, Dyer W, Magid D, O’Connor P, Beck A, et al. Health system factors and antihypertensive adherence in a racially and ethnically diverse cohort of new users. JAMA Intern Med. 2013;173:54–61.

29. Mehta SS, Wilcox CS, Schulman KA. Treatment of hypertension in patients with comorbidities: results from the study of hypertension prescribing practices (SHyPP). Am J Hypertens. 1999;12(12 Pt 1):1–24.

30. Tuhim S, Cooperman A, Rojas M, Brust JC, Koppel B, Martin K, et al. The association of race and sex with the underuse of stroke prevention measures. J Stroke Cerebrovasc Dis. 2008;17:226–34.

31. Ballard DJ, Strogatz DS, Wagner EH, Siscovick DS, James SA, Kleinbaum DG, et al. Hypertension control in a rural southern community: medical care process and dropping out. Am J Prev Med. 1988;4:133–9.

32. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:1957–63.

33. Hyman DJ, Pavlik VN, Vallbona C. Physician role in lack of awareness and control of hypertension. J Clin Hypertens. 2000;2:324–30.

34. Cruz-Flores S, Rabinov R, Biller J, Kuppermann N, Gorelick PB, et al. Racial-ethnic disparities in stroke risk factors: the impact of socioeconomic status. Stroke. 2003;34:2243–22.

35. Daugherty S, Hinkle E, Kuppermann N, Gorelick PB, et al. Racial-ethnic disparities in stroke care: the American experience: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:901–16.

36. Levine DA, Neidecker MV, Kiefe CI, Karve S, Williams LS, Allison JJ. Racial/ethnic disparities in access to physician care and medications among US Medicare patients with type 2 diabetes lowers hemoglobin A1c. J Manag Care Med. 2012;15:39–46.

37. Bosworth HB, Olsen MK, Neary A, Orr M, Gruber JJ, Svetkey L, et al. Take Control of Your Blood Pressure (TCBY) study: a multifactorial tailored behavioral and educational intervention for achieving blood pressure control. Patient Educ Couns. 2008;70:38–47.

38. Gabbay RA, Lendel I, Salsen TM, Sheffer G, Adelman AM, Mauger DT, et al. Nurse care management improves blood pressure, emotional distress and diabetes complication screening. Diabetes Res Clin Pract. 2007;71:28–35.

39. Bosworth HB, Olsen MK, McCant F, Harrelson M, Gentry P, Rose C, et al. Hypertension Intervention Rape Telemedicine Study (HINTS): testing a multifactorial tailored behavioral/educational and a medication management intervention for blood pressure control. Am Heart J. 2007;153:918–24.

40. Stamp KD, Allen NA, Lehrer S, Zagarins SE, Welch G. Telehealth program for Medicaid patients with type 2 diabetes lowers hemoglobin A1c. J Manag Care Med. 2012;15:39–46.

41. Golden RR, Teresi JA, Kulraj BI. Development of indicator scales for the Comprehensive Assessment and Referral Evaluation (CARE) interview schedule. J Gerontol. 1984;39:138–46.

42. Teresi JA, Golden RR, Kulraj BI. Concurrent and predictive validity of indicator scales developed for the Comprehensive Assessment and Referral Evaluation interview schedule. J Gerontol. 1984:39:158–65.

43. Teresi JA, Golden RR, Kulraj BI, Wilder DE, Bennett RG. Construct validity of indicator-scales developed from the Comprehensive Assessment and Referral Evaluation interview schedule. J Gerontol. 1984:39:147–57.

44. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697–716.

45. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med. 2007;167:141–7.

46. Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Pinera RS, et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology. 2005;25:153–52.

47. Sawyer J, Warach S, Janis S, Osterloh J, Becker K, Benavente O, et al. Standardizing the structure of stroke clinical and epidemiologic research data: the National Institute of Neurological Disorders and Stroke (NINDS) Stroke Common Data Element (CDE) project. Stroke. 2012;43:967–73.

48. Charlton ME, Pompei P, Alex KL, Mackenize CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.

49. Dubois B, Stachuyev A, Lithou J, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55:1621–6.

50. Pikonis PA, Choi SW, Reise SP, Stover AM, Riley WT, Cella D, et al. Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS®): depression, anxiety, and anger. J Chronic Dis. 1987;40:373–83.

51. Mahoney FI, Wood OH, Barthel DW. Rehabilitation of chronically ill patients: the influence of complications on the final goal. South Med J. 1958;51:605–9.

52. The EuroQol Group. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.

53. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10:348–54.

54. Thompson FE, Midthune D, Subar AF, Kipnis V, Kahle LL, Schatzkin A. Development and evaluation of a short instrument to estimate usual dietary intake of percentage energy from fat. J Am Diet Assoc. 2007;107:760–7.

55. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35:1381–95.
60. Shea S, Weinstock RS, Teresi JA, Palmas W, Starren J, Cimino JJ, et al. A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus: 5 year results of the IDEATel study. J Am Med Inform Assoc. 2009;16:446–56.

61. Green BB, Cook AJ, Ralston JD, Fishman PA, Carz SL, Carlson J, et al. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA. 2008;299:2857–67.

62. McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet. 2010;376:163–72.

63. Cohen J. Statistical power analysis for the behavioral sciences. New York: Academic; 1988.

64. Diggle PL, Liang K-Y, Zeger SL. Analysis of longitudinal data. New York: Oxford University Press; 1994.

65. Liu G, Liang KY. Sample size calculations for studies with correlated observations. Biometrics. 1997;53:937–47.

66. Fleiss J. Design and analysis of clinical experiments. New York: John Wiley and Sons; 1999.

67. Chomowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365:993–1003.

68. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine: panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1172–7.

69. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253–8.

70. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses: panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1339–41.

71. Kraemer HC, Wilson GT, Fairburn CG, Agras WS. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry. 2002;59:877–83.

72. Pincus T, Miles C, Froud R, Underwood M, Carnes D, Taylor SJ. Methodological criteria for the assessment of moderators in systematic reviews of randomised controlled trials: a consensus study. BMC Med Res Methodol. 2011;11:14.

73. Wang R, Ware JH. Detecting moderator effects using subgroup analyses. Prev Sci. 2011;14:111–20.

74. Clark CE, Smith LF, Taylor RS, Campbell JL. Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. BMJ. 2010;341:c3995.

75. Clark CE, Smith LF, Taylor RS, Campbell JL. Nurse-led interventions used to improve control of high blood pressure in people with diabetes: a systematic review and meta-analysis. Diabet Med. 2011;28:250–61.

76. Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T. Self-monitoring and other non-pharmacological interventions to improve the management of hypertension in primary care: a systematic review. Br J Gen Pract. 2010;60:e476–88.

77. Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2010;3:CD005182.

78. Kleinendorfer DO, Khoury J, Moomaw CJ, Kwell K, Woo D, Flaherty ML, et al. Stroke incidence is decreasing in whites but not in blacks: a population-based estimate of temporal trends in stroke incidence from the Greater Cincinnati/Northern Kentucky Stroke Study. Stroke. 2010;41:1326–31.

79. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44.